Edward Wang serves as Chairman of Pythia Biotech, bringing a formidable track record of executive leadership, strategic forming, negotiation, and corporate governance to Pythia Biotech. With over three decades of experience at the helm of multi-billion-dollar enterprises, he specializes in transforming innovative potential into scalable, global commercial success.

Throughout his distinguished career, Mr. Wang has held top executive roles, including serving as Board Director and President of USI Corporation and China Petrochemical Development Corporation. He has extensive experience navigating complex international markets, having previously acted as Acting General Manager of ICI China Ltd., Chief Representative of ICI China Ltd. Beijing office, where he pioneered massive cross-border investments and commercial expansion strategies. His expertise encompasses strategic forming and execution, change management, and organization development that foster continuous innovation.

At Pythia Biotech, Mr. Wang leverages his deep commercial acumen to guide the company's Go-to-Market strategy, fundraising, and regional market expansion, ensuring Pythia establishes the new commercial standard for human-relevant oncology models. He has served as Vice Chairman of the Petrochemical Industry Association of Taiwan; Executive Director of Chemical Society Located in Taiwan and holds an MBA from Andrews University and a B.Sc. in Chemistry from National Tsing Hua University.

As Chief Executive Officer of Pythia Biotech, Dr. Kien Thiam Tan merges high-level scientific achievement with aggressive business development to lead the company’s commercial strategy, fundraising, and platform expansion. A recognized authority in precision oncology, biomarker-driven drug development, and clinical pharmacology, he is dedicated to translating complex tumor biology into scalable, highly predictive clinical applications. 

Dr. Tan’s scientific foundation is highlighted by over 15 years of translational research and a portfolio of 37 publications in leading clinical oncology and medical journals. He maintains a highly active and visible presence within the global oncology community, with a proven track record of presenting early-phase clinical trial data and translational research at the world’s premier scientific meetings, including the ASCO Annual Meeting, the AACR Symposium, ESMO, and the Biomarker & Immuno-Oncology World Congress. 

Beyond his scientific contributions, Dr. Tan possesses sharp business acumen forged through extensive collaborations with top-tier key opinion leaders (KOLs), academic institutions, and biopharmaceutical partners across Taiwan, Japan, Singapore, and Hong Kong. Prior to Pythia, his executive leadership as Chief Scientific Officer at Anbogen Therapeutics and Director of Translational Genomic Medicine at ACT Genomics demonstrated his exceptional ability to bridge R&D with commercialization. In these roles, he successfully oversaw corporate strategy, Phase 1B/2 clinical trial execution, out-licensing evaluations, and the regulatory approval and launch of multiplex diagnostic platforms. 

Dr. Tan holds a Ph.D. in Molecular and Cell Biology from the National Defense Medical Center and Academia Sinica. His unique capacity to align rigorous global scientific validation with strategic market expansion ensures Pythia Biotech is perfectly positioned to capture market share and redefine the future of preclinical oncology.

Chin-Pei Chen drives corporate finance, human resources, and administrative operations at Pythia Biotech. With a comprehensive executive background that bridges the biotechnology and industrial manufacturing sectors, she plays a vital role in establishing the strict financial discipline and operational excellence required to scale Pythia's advanced preclinical platforms.

Prior to joining Pythia, Chin-Pei held top-tier executive roles, including serving as the Chief Financial Officer at Handa Biotek Co., Ltd. and as Vice President of Finance at Helian Chemical Co., Ltd. In these capacities, she successfully directed all facets of corporate finance, accounting, taxation, legal affairs, and human resources administration. Her extensive corporate management capabilities are further anchored by her tenure as a Manager at the China Petrochemical Development Corporation (CPDC), where she oversaw complex operational and human resources management for the large-scale industrial enterprise.

Chin-Pei holds a Master’s degree in International Economics from National Dong Hwa University and a Bachelor’s degree in International Trade from Fu Jen Catholic University. Her multidisciplinary expertise in navigating complex financial, legal, and human resource landscapes ensures that Pythia Biotech is built on a resilient, highly scalable operational foundation.

Dr. Ka-Po Tse is Head of Translational Oncology at Pythia Biotech. With more than 15 years of experience in cancer genomics, translational medicine, biomarker discovery, and molecular diagnostics, she focuses on biomarker-driven translational research that advances oncology drug development and precision medicine.

Dr. Tse’s career spans academic research, clinical laboratories, and the biotechnology industry. She was a postdoctoral fellow at Chang Gung University, where she studied genetic susceptibility and prognosis in nasopharyngeal carcinoma. At ACT Genomics, she established and managed the Singapore clinical laboratory and later served as Scientific Researcher, performing NGS-based comprehensive genomic profiling and curating clinically relevant variants. At AnBogen Therapeutics, she led translational research strategy for multiple oncology biomarker programs and contributed to the design and management of biomarker studies in two Phase I/II clinical trials.

Her research covers nasopharyngeal carcinoma, melanoma, breast cancer, and hepatocellular carcinoma, with 15 peer-reviewed publications in journals including the American Journal of Human Genetics, Cancer Research, and Clinical Cancer Research. She has long collaborated with clinicians, pathologists, bioinformaticians, and pharmaceutical partners across Asia, bringing strong cross-disciplinary and international collaboration experience.

At Pythia Biotech, Dr. Tse will advance translational oncology strategy and biomarker research and expand scientific collaborations across Taiwan, Singapore, and the Asia-Pacific region. She connects clinical needs with molecular insights to deepen the application of the TME-Chip in oncology drug development.

Dr. Tse holds a Ph.D. in Microbiology and Immunology from National Yang-Ming University and an M.S. in Life Science from National Tsing Hua University.

Karen Pan serves as Research Operations Lead at Pythia Biotech, where she drives the clinical alignment and patient-relevant validation of Pythia’s advanced tumor microenvironment (TME) models. With over 12 years of experience executing translational research within major medical centers, she plays a critical role in ensuring Pythia's organ-on-chip platforms deliver highly predictive, clinically actionable data for pharma partners.

Karen’s extensive background spans precision oncology, immunology, and medical device regulations. Prior to joining Pythia, she conducted specialized organ-on-chip research at National Tsing Hua University (NTHU) and investigated non-small cell lung cancer (NSCLC) tumor-promoting genes at Shuang Ho Hospital. She previously spent nearly a decade as a central research figure at the Drug Allergy Center at Linkou Chang Gung Memorial Hospital. There, she spearheaded human clinical trials, executed industry-academia technology transfers, and co-developed multiple patented rapid clinical diagnostic tests. Her operational leadership also included establishing and supervising new clinical testing laboratories internationally.

Holding an M.S. in Molecular Medicine from National Cheng Kung University and a B.S. in Life Sciences from National Chung Hsing University, Karen pairs her deep scientific expertise in molecular biology and proteomics with stringent regulatory knowledge. She holds advanced training in ISO 13485 (Medical Devices), ISO/IEC 17025, and pharmaceutical regulatory affairs, ensuring that Pythia’s platforms not only push the boundaries of science but also align seamlessly with global commercial and clinical standards.

Dr. Wei-Yu Chen serves as a Scientist at Pythia Biotech, where he plays a pivotal role in expanding the company's highly predictive preclinical platforms. Leveraging his deep expertise in immunology and pharmaceutical R&D, Dr. Chen leads the development and clinical validation of Pythia’s newest organ-on-chip models, driving the next wave of human-relevant drug discovery.

Dr. Chen earned his Ph.D. in Basic Medical Sciences from China Medical University and his M.S. in Immunology from Chung Shan Medical University. During his doctoral training, he received multiple graduate research awards and published 16 SCI-indexed journal articles, including two first-author publications in Q1-ranked journals.

Prior to joining Pythia Biotechnology, Dr. Chen served as Head of the Animal Research and High-Throughput Screening (HTS) Team at CMC Magnetics Corporation. He also acted as a Sponsor Monitor for the company’s contract research organization (CRO) programs, overseeing preclinical studies, quality management, and cross-functional project coordination. During his tenure, he established and optimized multiple research platforms and workflows, significantly improving R&D efficiency and data quality. He contributed to drug development programs that successfully obtained U.S. FDA approval to enter Phase II clinical trials. In addition, he led the management and optimization of animal research facilities, strengthening animal welfare and quality management systems, which resulted in improved IACUC evaluation outcomes and operational performance.

He later joined Tripartite Therapeutics Inc. (TTI) as a Scientist, where he continued to focus on drug discovery and development, efficacy and safety evaluation, and translational preclinical research. Through these roles, he accumulated extensive experience in industrial R&D, project management, and interdisciplinary collaboration.

With a strong academic foundation and broad industry experience, Dr. Chen continues to drive the development and validation of Pythia’s organ-on-a-chip platforms, with the goal of establishing more clinically predictive cancer research models that accelerate translational research and oncology drug development.

Dr. Yi-Chen Lin is a Scientist at Pythia Biotech, specializing in translational oncology, tumor immunology, and oncology drug development. He received his Ph.D. in Life Sciences from the National Defense Medical Center and Academia Sinica, where his research focused on the molecular and cellular mechanisms underlying cancer progression and therapeutic response.

Prior to joining Pythia, Dr. Lin served as a Scientist at Anbogen Therapeutics, where he contributed to the development of novel oncology therapeutics across multiple cancer types, including pancreatic cancer, hepatocellular carcinoma, and urothelial carcinoma. His experience spans preclinical translational research, biomarker strategy development, PK/PD study design, and mechanism-of-action investigations.

At Pythia, Dr. Lin supports the development and application of the TME-Chip platform by integrating tumor biology, translational research, and biomarker science. His work focuses on generating human-relevant insights that help researchers better understand therapeutic response, identify predictive biomarkers, and accelerate oncology drug development.

Dr. Kanishk Singh is a biomedical engineer specializing in biosensors, bioelectronics, microfabrication, and medical device development. He holds a Ph.D. in Electronics Engineering from Chang Gung University and has conducted postdoctoral research at National Yang Ming Chiao Tung University and National Chung Hsing University.

His interdisciplinary expertise spans thin-film deposition, semiconductor device fabrication, electrochemical sensing, flexible electronics, microfluidics, and biomaterial-based wearable sensors. He has developed diagnostic platforms for detecting biomarkers including EGFR, cardiac troponin, glucose, dopamine, and allergens, and is a co-inventor of a U.S. patent related to prostate cancer screening.

At Pythia Biotech, Dr. Singh contributes to the development, engineering, and optimization of microphysiological systems, supporting the translation of advanced bioengineering technologies into reliable and scalable research platforms.

Chia-Hua (Neo) Hou serves as a Scientist at Pythia Biotech, bringing a highly specialized, cross-disciplinary background in precision oncology, advanced molecular imaging, and GMP-compliant cell manufacturing. At Pythia, his deep familiarity with tumor microenvironment (TME) research and preclinical drug evaluation is instrumental in validating the clinical predictive power of our human-relevant organ-on-chip platforms. By bridging in vivo and in vitro methodologies, he leads the application of complex animal models to our tumor-on-chip platforms for rigorous drug efficacy and biocompatibility studies.

Before joining Pythia, Chia-Hua built a formidable track record across leading research institutes and biotechnology firms, establishing novel experimental platforms and independently executing complex R&D projects. As an Associate Researcher at TEMeds, he drove the development of targeted radiopharmaceuticals, overseeing radioisotope handling, biodistribution, and pharmacokinetic evaluations.

Prior to this, he spent over five years at Meridigen, advancing to Cell Manufacturing Deputy Manager. There, he spearheaded the GMP/GTP manufacturing of umbilical cord mesenchymal stem cells, drove process optimization, and managed cleanroom operations. He began his career at the National Atomic Research Institute (NARI), developing orthotopic liver cancer models and pioneering molecular imaging techniques using small animal PET/CT and MRI.

With extensive hands-on experience in diverse cancer cell culture, sterile biomanufacturing, and nuclear medicine contrast agent development, Chia-Hua possesses a unique ability to align complex laboratory execution with strategic preclinical objectives. His proven capabilities in cross-departmental collaboration and process optimization ensure that Pythia’s TME-chip validation processes meet the highest standards of scientific rigor and global regulatory compliance.

Wen-Chen Chu serves as an Scientist at Pythia Biotech. She brings over 10 years of extensive research and development experience, specializing in microfluidics, cellular biology, and tissue engineering. At Pythia, her multidisciplinary skill set supports the rigorous development, fabrication, and biological validation of our advanced in vitro platforms. 

Prior to joining Pythia, Wen-Chen spent over ten years as a Research Assistant at CellMax Life , where she focused heavily on the manufacturing and process optimization of microfluidic chips. During this time, she honed her technical proficiency in precision manufacturing tools, including the operation of laser engravers and surface profiler. 

Her technical expertise extends deeply into biological quality assurance and advanced cell models. As a Quality Engineer at Acrocyte Inc. she was responsible for incoming quality control (IQC), maintaining ISO 13485, and conducting specialized 3D spheroid cell cultures. Earlier in her career, she served as a Research Assistant at the National Defense Medical Center, where she isolated and cultivated human umbilical cord mesenchymal stem cells (MSCs) and utilized flow cytometry to monitor their differentiation. 

Wen-Chen holds an M.S. in Molecular Medicine from National Tsing Hua University and a B.S. in Life Sciences from Tzu Chi University. Her graduate research established a strong foundation in tissue engineering, focusing on pioneering cell patterning methods utilizing magnetic particles and light-sensitive hydrogels. Her unique integration of microfluidic engineering, cellular biology, and quality management is a vital asset in scaling Pythia's human-relevant platforms.

Early in his career Daniel found his feet in leardership roles progressing quickly to management. He has successfully overseen fit out projects throughtout Australia which lead to him establishing Finch Kitchens and Joinery in 2004 as a 25 years old.  Daniel continued to further his formal education and business management skills to relaunch a Finch Projects in 2013.  Daniel boast an impressive 20 years industry experience as well as qualification including Certifcates IV in Frontline Management, Trade Certifcate in Cabinet Making and Certifcate II in Emergency Medical Service.  Daniel has enormous respect for customer service and has the belief that there is no great compliment than a recommendation from a client.

Yen Xin Ng currently serves as a Business Operations Associate at Pythia Biotech, where she supports business operations management, administrative management, project coordination, and cross-functional collaboration. She works closely with the R&D, business development, and management teams to facilitate operational initiatives. Leveraging her experience in project management and process planning, she contributes to the establishment of standardized operating procedures, optimization of operational processes, and enhancement of team efficiency, supporting the company’s growth and organizational development.

Yen Xin earned her Bachelor’s degree in Medical Laboratory Science and Biotechnology from Taipei Medical University. With an academic background in medical laboratory science, biotechnology, and life sciences, she possesses a strong understanding of the healthcare industry, biotechnology research and development processes, and laboratory operations. By integrating her scientific knowledge with operational management capabilities, she provides cross-functional coordination and operational support to facilitate collaboration across the organization.

Prior to joining Pythia Biotech, Yen Xin worked in the healthcare industry, where she managed projects for multinational pharmaceutical companies, oversaw Patient Support Program (PSP) operations, and coordinated cross-functional collaborations. Through these experiences, she developed extensive expertise in project execution, process optimization, and quality management. Her responsibilities included project planning, Standard Operating Procedure (SOP) development, quality improvement initiatives, Pharmacovigilance (PV) operations management, and coordination with internal teams and external partners. With strong project management capabilities, systematic thinking, and execution skills, she continues to connect R&D, administrative, and business teams, streamline operational processes, enhance organizational efficiency, and support the company’s technological advancement and commercialization efforts.